Repurposing melatonin for its potential roles in gastrointestinal cancers: highlighting the molecular mechanisms Authors: Kiana Yousefipour, Seyed Soheil Razavi Rohani, Sayed Mohammad Mahdi Hosseini, Kianaz Kafilzadeh, Nafiseh Sadat Alavi, Negar Firouzabadi Published: 2026 ABSTRACT Gastrointestinal (GI) cancers are among the most common cancers of the decade, many of which have a poor prognosis. Due to the high prevalence of toxicity and adverse drug reactions (ADRs) of chemotherapeutic agents and low patient compliance, there is always a need for drugs that can be used as adjuvants to existing cancer treatments with low ADRs which can boost the efficacy of chemotherapeutics and reduce the associated toxicities. Repurposing or repositioning a drug with known pharmacological properties is of great value in this context. Drug repurposing has been applied in many illnesses in the recent decade. Melatonin is an endogenous hormone with multiple anticancer properties. It demonstrates antitumor effects by modifying several critical signaling pathways, inhibiting proliferation and metastasis, inducing apoptosis and autophagy, and also reducing oxidative stress. It also reduces toxicity of chemotherapeutics. Due to specific characteristics of melatonin and its limited toxicity, melatonin can be considered as a potential for repositioning in various cancers. Hence, melatonin can be included as an off-label adjuvant chemotherapy to improve the prognosis and overall quality of life of patients suffering from GI cancers. Herein, the action of melatonin on various GI cancers, with the emphasis on its effect on major oncogenic signaling pathways (e.g., Wnt/β-catenin signaling pathway, phosphatidylinositol 3-kinase/protein kinase B (PI3K/Akt), and nuclear factor kappa B (NF-κB)) are discussed. Additionally, mechanisms by which melatonin halts the process of mitosis, induces apoptosis, and makes tumors more vulnerable to chemotherapy are discussed.Graphical abstract Introduction Gastrointestinal (GI) malignancies impact the digestive tract and other abdominal organs. The esophagus, stomach, colon, rectum, liver, and pancreas are the primary forms of GI cancers. It is estimated that each of these cancers caused over 500,000 cases in 2022 [1]. Due to the high prevalence of toxicity and adverse drug reactions (ADRs) of chemotherapeutic agents and low patient compliance, there is always a need for compounds that can be used as adjuvants to existing cancer treatments with low ADRs, which can boost the efficacy of chemotherapeutics [2]. Cancer drug discovery involves time-taking process as well as an enormous budget, followed by pre-clinical and clinical studies to evaluate pharmacokinetic properties and possible toxicities of a drug. Hence, repurposing/repositioning of a drug with known pharmacological properties is of great value in every illness, such as cancer [3–8]. Thus, repurposing of drugs that are Food and Drug Administration (FDA)-approved may have the potential of being used as an adjuvant treatment. Melatonin (N-acetyl-5-methoxytryptamine) is a hormone released by the pineal gland and other organs such as the GI tract, kidneys, retina, and skin that has pleiotropic effects [9]. Melatonin is an indoleamine produced by the pineal gland and has long been implicated in the regulation of circadian rhythms. Melatonin plays a multitude of roles unrelated to its better-known association with sleep [10]. Numerous biological processes (circadian rhythm), endocrine modulation, anti-inflammatory, anti-aging, anti-tumor, and free radical scavenging are all influenced by melatonin [11]. According to recent studies, melatonin inhibits the migration of cancer cells, induces apoptosis and autophagy, and modifies oxidative stress pathways to have anti-cancer effects [12]. MT1 and MT2 are the particular melatonin receptors, which are the members of the seven-transmembrane G protein-coupled receptor family, that control a wide range of physiological processes [13]. Melatonin indirectly inhibits the negative tendency of healthy cells to become cancerous by down-regulating the following growth factors: prolactin, insulin-like growth factor-1 (IGF-1), growth hormone-dependent growth factors (GHFs), epidermal growth factor receptor (EGFR), vascular endothelial growth factor (VEGF), hepatocyte growth factor (HGF), transforming growth factor (TGF), and platelet-derived growth factor (PDGF) [14]. Melatonin may either directly or indirectly influence pathogenic signaling pathways by influencing their upstream processes, which are mostly mediated by Mitogen-activated protein kinase/Extracellular signal-regulated kinase (MAPK/ERK), phosphatidylinositol 3’ kinase/Protein kinase B (PI3K/AKT), and c-Jun N-terminal Kinase (JNK) pathways. Additionally, melatonin inhibits invasion, migration, and proliferation by lowering DNA repair capacity, which makes tumor cells more susceptible to chemotherapy and radiotherapy [9]. Melatonin has been demonstrated in studies to reduce intestinal peristalsis, improve the immune system of the GI tract, control stool moisture, and shield the digestive system from stomach acid and digestive enzymes [15]. Experimental studies demonstrate that melatonin enhances the sensitivity of cancer cells to conventional treatments such as chemotherapy and radiotherapy, reducing their side effects and improving overall outcomes [16]. Through MT1 and MT2 receptors, melatonin influences the islet cells of the pancreas, which in turn produce insulin, glucagon, and somatostatin [17]. In both in vitro and in vivo conditions, melatonin inhibits the cell cycle to provide a variety of anti-proliferative effects. Adenyl cyclase and cyclic adenosine monophosphate (cAMP) are suppressed by activating the receptors of MT1 and MT2, which decreases the absorption of linoleic acid, a source of tumor growth [18, 19]. Cancers of the GI tract display crucial differences and are very intricate; many different pathways are involved in triggering, growing, and spreading the tumor. Some of the important pathways include the Wnt/β-catenin signaling pathway, Hippo/YAP pathway, and Interleukin-6 (IL-6)-related cytokine signaling, among others. The lack of control of these pathways leads to worse survival rates due to aggressive tumor behavior [20]. For example, the Wnt/β-catenin signaling pathway has already been established as one of the primary targets for therapy because of its alteration in numerous GI cancers [21]. More recent studies have explained the functions of certain pathways in the context of GI cancers. The Hippo/YAP signaling pathway, for instance, plays an important role in controlling cell growth and cell division. Disruptions in this pathway, especially regarding the YAP protein, may contribute to the pathogenesis of multiple GI malignancies, suggesting possible targets for treatment [22]. Moreover, the IL-6 cytokine pathway can activate both the Src family kinases and the YAP pathway, further implicating these pathways in enhancing tumor progression and inferring new therapeutic strategies for colorectal cancer [23]. A multitude of clinical trials that focus on treating GI cancers are evaluating therapies aimed at correcting pathway alterations. The mammalian target of rapamycin (mTOR) signaling pathway has been treated with new therapeutic agents over the last few years, which appear to increase the responsiveness of treatment to many types of GI cancers [24]. Numerous investigations into melatonin’s oncostatic activity concerning hormone-dependent mammary tumors focus on its antiestrogenic properties. For example, melatonin at a physiological concentration of 1 nM reversibly modulates cell proliferation and increases levels of p53 and p21/WAF1, alters cell cycle, and decreases metastatic potential of breast cancer cells in the presence of serum or estradiol [25]. Melatonin at 0.5 mM and 1.0 mM has been shown to reduce in a dose-dependent manner proliferation, migration, and invasion, and to increase apoptosis in hepatocellular carcinoma (HCC) cells [26]. Melatonin has demonstrated anticancer effects in in vivo studies. When melatonin was given to experimental colon carcinoma in mice and rats, it showed a slowing of the colon cancer development [25]. Considering the variety of GI cancers, this review focuses on pathway-modulating the effects of melatonin on specific types of GI cancers. The esophageal, gastric, colorectal, and pancreatic cancers, in addition to HCC, are reviewed, and the role of melatonin in the regulation of specific pathways in each of the mentioned cancers, including Wnt/β-catenin, PI3K/Akt/mTOR, MAPK/ERK, Hippo/YAP, NF-κ β, IL-6 signaling, oxidative stress, apoptosis, and autophagy are discussed. The graphical abstract summarizes the main signaling pathways involved in the effect of melatonin on different GI cancers. Chemical structure of melatonin The molecular structure of melatonin is described as N-acetyl-5-methoxytryptamine, indicating a methoxy group at the 5-position of the indole ring and an acetylated amine group at the terminal end, with a bicyclic indole ring system fused to a six-membered benzene ring, an acetamide side chain, and a methoxy group as key substituents [27]. The main biological producer of melatonin is the pineal gland, which acts through certain receptors that are unevenly located throughout the brain and body tissues [28]. Melatonin receptors (MTs) in GI cancers Melatonin receptors, MT1 and MT2, are G protein-coupled receptors with seven transmembrane (TM)-spanning α-helical segments being connected by alternating intracellular and extracellular loops. The amino terminus is situated on the extracellular side, while the carboxyl terminus is on the intracellular side. Stretches of 20 to 25 predominantly hydrophobic residues that span the cell membrane are present in these seven α-helical segments [29]. The MT1 and MT2 melatonin receptors’ differential affinities account for their categorization. In the context of gastroenterology oncology, these receptors are expressed in the epithelium of the stomach and colon [15, 30]. In addition to murine Colon 38 cancer cells, melatonin receptors mRNA expression shows that MT1 and MT2 are present in numerous malignancies [31]. In the mucosa of the small intestine, MT2 expression predominates over MT1 [32]. For several years, the melatonin receptors have been proposed for their anti-GI cancer effects [33]. Along with MT1 and MT2 is the MT3 receptor. MT3 receptors are cytoplasmic receptors which are located in many tissues including the liver and the intestines [34]. MT1a (Mel 1a, ML1a, ML1, MT1, MTNR1A), MT2 and MT3 signaling On the fourth human chromosome is the MT1 receptor, which consists of 351 amino acids. MT1 receptors are commonly localized in the human skin, ovarian granulosa cells, and the suprachiasmatic nucleus (SCN) and can bind to different G-proteins to mediate effects. G-proteins then lead to the inhibition of adenylate cyclase and subsequently the reduction of cAMP production [35, 36]. MT1 receptor activation can also lead to the activation of phospholipase C beta (PLCβ) [37]. MT1 modulates transcriptional activity of nuclear receptors like estrogen receptor alpha (ERα) and retinoic acid receptor alpha (RARα) through melatonin’s binding. Melatonin receptors (mainly MT1 and MT2) are ligated by endogenous melatonin as well as synthetic drugs, ramelteon and agomelatine, among others, that are crucial for circadian rhythms, sleep, and many other physiological processes [38]. Although the MT1 and MT2 receptors feature fairly conserved binding pockets for melatonin, they also take distinctive conformational states that modulate ligand selectivity, important for designing subtype-specific therapeutics [39]. The MT1 receptor is more associated with vasoconstriction and MT2 with vasodilation, indicating different functional roles for vascular physiology in the members [40]. MT1 and MT2 receptors build the blueprint of sleep regulation both play an integral differential role in the architecture and adjustment of sleep. MT1 receptors mainly control rapid eye movement (REM) sleep; MT2 receptors are mainly responsible for non-REM (NREM) sleep modulation. There is evidence that melatonin receptors are participants apart from affecting circadian rhythm, also interactive effects on sleep homeostasis and homeostatic circadian interplay of sleep [41]. It has been demonstrated that the disulfide link that forms between Cys113 and Cys190 is crucial for preserving the proper conformation of the MT2 receptor, allowing for ligand interaction to take place without changing the receptor’s expression on the cell surface. MT2 receptor expression has been identified in various tissues and organs, such as the immune and reproductive systems, brain, hypothalamus/SCN, retina, pituitary gland, blood vessels, reproductive cells and tissues, testes, kidneys, GI, mammary gland, adipose tissue, and skin. However, its distribution is more restricted than that of the MT1 receptor [42]. MT3 receptor is a quinone reductase 2 enzyme, a cytosolic flavoenzyme, that inhibits electron transferring of quinine leading to prevention of oxidative stress and the harmful effects of free radicals [43]. MT3 receptors may affect the expression of enzymes involved in detoxification and suppress proliferation [44, 45]. However, they are some debates on whether melatonin serves as a potential ligand of quinone reductase 2 enzyme [46, 47]. Research has shown that the melatonin MT1 receptor can be found in intracellular sites, including the mitochondria. MT1 receptor-dependent changes in mitochondrial activity have been a part of the proposed mechanisms that explain the neuroprotective effects of melatonin in neurodegenerative diseases. Melatonin has been shown to inhibit the release of cytochrome c from isolated brain mitochondria, indicating that melatonin may act on MT1 receptors that are located in the brain mitochondria. More recently, studies using cell-impermeable melatonin receptor agonists have demonstrated the mitochondrial localization of MT1 receptors and differentiated between MT1-induced Gi/cAMP signaling at the cytoplasmic surface and at the mitochondria [45]. Biological roles and mechanism of action of melatonin Melatonin is synthesized from tryptophan, which is converted to serotonin in other regions of the brain via a pathway. Some of the produced serotonin is transported to the pineal gland, where it is subjected to a cyclical, light-dependent process in order to be converted to melatonin. The SCN of the hypothalamus regulates the conversion of serotonin to melatonin, which is responsible for the coordination of the body’s circadian rhythms. The retina transmits information about varying light conditions, from low light to darkness, to the SCN via the retinohypothalamic tract. The superior cervical ganglion, which innervates the pineal gland, receives signals from the SCN through the sympathetic nervous system [48]. Melatonin helps control the body’s natural rhythms by acting on a part of the brain called the SCN; it serves as a hormone that signals when it is light or dark and helps manage changes in body systems over time [49]. Hormones, energy, and sleep-wake cycles are all regulated by melatonin receptors (MT1 and MT2). Since melatonin boosts the activity of both endogenous and exogenous antioxidant enzymes, gets rid of free radicals, and shields cells from oxidative damage, melatonin is regarded as a potent antioxidant [38]. Melatonin, known as the “hormone of darkness,” helps protect cells from free radicals and is produced in mitochondria, working by influencing gene expression in both the nucleus and mitochondria [50, 51]. Melatonin has anti-inflammatory and antioxidant properties. Specifically, the aromatic indole ring of melatonin acts as a buffer and scavenges reactive oxygen species (ROS) and nitrogen species (RNS). This antioxidant scavenging effect is multiplied by the downstream antioxidant activity of its reaction products and metabolites in a cascade-like manner. Also, melatonin encourages the endogenous antioxidant enzymes, like superoxide dismutase (SOD), catalase (CAT), glutathione peroxidase (GPX), and glutathione reductase (GR), to be produced [52]. The large concentration of melatonin in mitochondria safeguards proteins, lipids, and DNA from oxidative damage induced by free radicals [53]. The neuroprotective properties of melatonin are crucial in enhancing the prognosis of neurodegenerative diseases, including Parkinson’s disease. Melatonin inhibits the nuclear factor kappa B (NF-κB) pathway, which in turn limits its impact on local inflammatory responses by blocking inducible nitric oxide synthase (iNOS) synthesis in macrophages and microglia. Additional signaling pathways that melatonin can affect include upregulation of nuclear factor erythroid 2-related factor 2 (NRF2), the activation of the Toll-like receptor-4 (TLR4) and the high-mobility group box-1 (HMG-1) signaling receptors, and inhibition of NOD-, LRR- and pyrin domain-containing protein 3 (NLRP3) inflammasome [54]. Conventional therapeutic applications of melatonin Melatonin and sleep disorders Melatonin increases the rapid resetting of circadian cycles in subjects with night shifts, jet lag, and insomnia, leading to sleep improvement and mood enhancement [49, 55]. Melatonin attenuates the wake-promoting signal of the circadian clock at the SCN in humans and other diurnal species, thereby promoting sleep. Furthermore, melatonin induces sleep-like alterations in the activation of the precuneus and promotes fatigue by acting on the default mode network (DMN) regions of the brain [56]. Melatonin, muscles and metabolic health Melatonin aids muscle regeneration/hypertrophy by reducing oxidative stress while improving insulin sensitivity concerning metabolic disorders such as diabetes [57]. A decrease in urinary melatonin in postmenopausal women was associated with sarcopenia, and in castrated male rats, the melatonin supply slowed muscle atrophy, operating as testosterone [58]. Melatonin and stem cell therapy Melatonin receptors MT1 and MT2 are expressed in human mesenchymal stem cells (MSCs). Melatonin is known for its ability to enhance the function of MSCs through its cognate receptors. Pretreatment with melatonin improves the therapeutic potential of MSCs by maintaining their self-renewal during in vitro proliferation [59]. In some malignancies, including glioma, breast, ovarian, colon, and osteocarcinoma, melatonin can target cancer stem cells (CSCs) as a tumor suppressor. Melatonin has the potential to modulate the primary signaling pathways that are associated with self-renewal and survival of CSCs. In conclusion, melatonin may act as a promising therapeutic agent in cancer treatment by targeting CSCs. Nevertheless, the concentration of melatonin used in in vitro investigations was significantly higher than the concentration applied to patients for the clinical treatment of cancer [60]. Melatonin and cardiovascular diseases Melatonin prevents oxidative damage, reduces inflammation, and improves kidney protection that prevents different heart diseases [57]. Melatonin was discovered to alleviate arterial hypertension in rodents that were generated through assisted reproductive technologies. This was due to its capacity to regulate nitric oxide levels by preventing the impaired methylation of endothelial nitric oxide synthase. Melatonin has also been shown to alleviate the symptoms of both macrovascular and microvascular diseases. Melatonin administration restored the endothelial function and vascular responses of streptozotocin-induced diabetic rats and high-fat diet rats [61]. In hypertension patients, melatonin has the potential to inhibit nocturnal blood pressure and modulate heart rate. Additionally, melatonin may function as a potent protective agent in the cardiovascular system, significantly reducing the likelihood of developing reperfusion injury following myocardial infarction [62]. Melatonin and cancer therapy Melatonin has the potential to induce apoptosis in cancer cells, obstruct tumor metastasis, and inhibit angiogenesis in a variety of malignancies, including ovarian, melanoma, colon, and breast cancer. Consequently, its potential therapeutic application in cancer treatment Approved [60]. Pancreatic cancer (PC) Pancreatic cancer (PC) accounts for about 2% of all malignancies, and its prevalence has grown recently [63]. The American Cancer Society estimates that PC ranked third after lung and colorectal cancer in the United States in 2019, with about 56,000 new cases and 40,000 fatalities [64]. Based on GLOBACAN reports, 2025, PC is estimated to have 549,000 cases worldwide [65]. In addition to being extremely invasive, PC has a high mortality rate, particularly in those between the ages of 65 and 80 [66]. Smoking is thought to be responsible for 20% of PC deaths worldwide, followed by diabetes at 9% and obesity at 6% [3]. About 5–10% of instances of PC are due to inherited genetic predisposition [29]. Familial PC, hereditary pancreatitis, and several hereditary tumor predisposition syndromes are examples of inherited risk factors [67]. With a 5-year overall survival of barely 5–10% and the highest incidence-to-mortality ratio of any solid tumor, PC has one of the highest mortality rates among cancers [68]. Some of the traditional treatments for PC include palliative care, radiation therapy, chemotherapy, immunotherapy, and surgery [63]. A comprehensive strategy that incorporates many treatment modalities, such as surgery, radiotherapy, chemotherapy, and newer treatments including immunotherapy and targeted therapy, is needed to manage PC [69]. It is of note that only 15–20% of patients with pancreatic tumors can have them removed; as a result, their post-operative long-term survival is poor [70]. Less than 9% of people with PC survive five years after diagnosis, and the disease is only diagnosed when it is advanced [71]. Signaling of melatonin in PC PC leads to any disruption of various signaling pathways, such as Hedgehog, TGF-β, and Notch, and transcription factors, such as pancreatic and duodenal homeobox 1 (PDX1, also known as insulin promoter factor 1, IPF1), homeobox gene HB9 (HLXB9), pre-B-cell leukemia homeobox 1 (PBX1), myeloid ecotropic viral integration site (MEIS), and Islet-1 (ISL1) [72]. Various theories have been proposed to explain how melatonin affects cancer [73]. Research has indicated that high dosages of melatonin may be used as an adjuvant treatment for PC [74]. By controlling Hypoxia-Inducible Factor-1 (HIF-1), melatonin can influence the metabolism of cancer. Under hypoxic conditions imitated by cobalt chloride, melatonin decreased VEGF and HIF-1α in PC cells (PANC-1), human lung adenocarcinoma (A549), and cervical cancer (HeLa) cell lines [75]. Melatonin has the potential to be used as a combination therapy option in pancreatic ductal adenocarcinoma (PDAC) because, in addition to modulating the Kirsten rat sarcoma viral oncogene homolog (KRAS), it upregulates the tumor suppressor genes p21, p27, and p57 in combination with cisplatin and cetuximab [76]. Melatonin may control cell survival and proliferation by activating caspase-3 and altering the expression of cyclins A and D [74]. In one study, the effects of melatonin on pancreatic stellate cells in pancreatic tumors showed that melatonin treatment activated antioxidant responses, including the expression of antioxidant enzymes regulated by NRF2 and SOD. This allowed the cells to control the potential pro-oxidative conditions caused by hypoxia. It also resulted in reduced activation of the inflammatory pathway and decreased cytokine expression [77]. Melatonin has protective effects on the endocrine and exocrine systems of the pancreas. It neutralizes ROS and maintains the integrity and cellular function of pancreatic tissues. It also improves ATP production and mitochondrial activity, while reducing mitochondrial permeability transition. By suppressing caspase activation and modifying B-cell lymphoma 2 (Bcl-2) family proteins, melatonin also promotes cellular viability. Thus, in pancreatic cells under stress, melatonin prevents necrosis and apoptosis [17]. It has been demonstrated that the prognosis of patients with PC is correlated with the expression of Platelet-derived growth factor receptor beta (PDGFR-β) in pancreatic stellate cells [78]. One of the main signaling pathways that is commonly interfered with in PDAC is activin/TGF-β [79]. Melatonin inhibits the expression of monoacylglycerol lipase (MGLL), promoting PC through the P-AKT/AKT (Protein kinase B) signaling pathway. On the contrary, the inhibition of the P-AKT/AKT signaling pathway by melatonin inhibits tumor growth and invasion through down-regulation of MGLL [80]. By inhibiting the PDGFR-β/STAT3 (Platelet-derived growth factor receptor beta/Signal transducer and activator of transcription 3) signaling pathway and the melatonin receptors, melatonin and sorafenib combination suppress PC. The combined effect facilitates further suppression of tumor cells by altering the activation of a transcription factor, known to enhance survival and proliferation, called STAT3 [43]. In pancreatic stellate cells under hypoxic conditions, melatonin induces apoptosis, modifies cyclin expressions, and initiates phosphorylation of MAPK, thereby reducing the viability of stellate and pancreatic cancer cells, and subsequently, impacting the tumor microenvironment and tumor progression [81]. In summary, the receptor-dependent and receptor-independent effects of melatonin in PC are as follows: Receptor‑dependent effects of melatonin in PC: In PDAC models, melatonin in combination with sorafenib inhibits tumor growth by PDGFR-β/STAT3 signaling blockade and melatonin receptor-mediated STAT3, and further increases mitochondrial dysfunction and apoptosis in tumor cells. Melatonin inhibits the expression of MGLL, promoting PC through the P-AKT/AKT signaling pathway. On the contrary, the inhibition of the P-AKT/AKT signaling pathway by melatonin inhibits tumor growth and invasion through down-regulation of MGLL. Receptor-independent effects of melatonin in PC: Under hypoxic conditions imitated by cobalt chloride, melatonin decreases VEGF and HIF-1α in PC cells (PANC-1), human lung adenocarcinoma (A549), and cervical cancer (HeLa) cell lines. Melatonin has been found to have protective effects on the pancreatic endocrine and exocrine systems. It neutralizes ROS, preserving the integrity and cellular function of pancreatic tissues. Additionally, it improves ATP generation and mitochondrial activity while decreasing the transition of mitochondrial permeability. By suppressing caspase activation and modifying Bcl-2 family proteins, melatonin also promotes cellular viability. Thus, in pancreatic cells under stress, melatonin prevents necrosis and apoptosis. Hepatic cancer Hepatic cancer remains a significant public health concern worldwide. Considered as the sixth most common cancer and the third resulting in cause of cancer-related deaths. The most common subtype of primary liver cancer is hepatocellular carcinoma (HCC), which constitutes approximately 75% of cases [82]. The burden of HCC is the highest in Asia and sub-Saharan Africa due to the prevalence of chronic hepatitis B virus (HBV) and aflatoxin exposure. In contrast, non-viral causes, including metabolic-dysfunction-associated steatotic liver disease (MASLD) and alcohol-related liver disease (ALD), are emerging as major contributors in Western countries [83, 84]. HCC is generally more prevalent in men than in women, with rates being two to three times higher in men. In over 20 countries, liver cancer is the leading cause of cancer death among men. Various risk factors, including HBV, develop HCC in the context of cirrhosis in most patients [83, 84]. Achieving a sustained virologic response (SVR) through antiviral therapy can reduce HCC risk by 50–80%, although it does not return to baseline levels, especially in those with cirrhosis. In a cohort of patients who achieved SVR, the risk of HCC was reduced by 76%, with an annual incidence of 0.9% [82, 85]. Addressing dyslipidemia, a component of metabolic syndrome, with statins may lower HCC risk by 37–42%. Individuals with high waist circumference have a 2-fold increased risk of HCC, independent of body mass index (BMI) [85, 86]. Combination therapies (e.g., atezolizumab + bevacizumab) have become standard first-line treatments. Immune checkpoint inhibitors like PD-L1 and CTLA-4 blockers are effective, especially in tumors linked to viral hepatitis [87, 88]. The cure rate of HCC is dependent on the cause of the disease, the stage of the disease at the time of diagnosis, and the management strategies that are used, and reflects the complexity of the disease and the importance of early intervention [89]. Long-term survival rates for HCC patients who achieve a cure may greatly differ according to treatment modalities and patient characteristics, with surgical resection and liver transplantation being the principal curative options, with liver transplantation generally providing better survival rates. Five years after liver transplantation, the overall survival (OS) was shown to be as high as 84.3%, while surgical resection was shown to have a pooled five-year OS of almost 56.2% [61]. Patients after curative procedures have approximately a five-year survival of around 45.5% [62]. Although the outcomes of curative treatments are limited, continuous development of treatment strategies, especially combination therapies, is necessary to improve the outcomes of patients with HCC [90]. However, the prognosis of advanced HCC remains poor, and therefore, there is a constant need for further research and new developments in treatment strategies [91]. Signaling of melatonin in HCC Melatonin has several roles in the development and progression of hepatic cancer, especially HCC. Evidence has shown that melatonin might exert a protective role in the development of liver carcinogenesis and reduce cancer incidence via dietary intake [92]. Also, melatonin has anti-cancer properties through cellular mechanism regulation, including RNA alternative splicing and metabolic pathway regulation, crucial for tumor growth and progression [93, 94]. Studies show that low levels of serum melatonin are related to poor prognosis in HCC, especially after liver transplantation, which suggests that melatonin could impact tumor development and survival [94]. Melatonin regulates RNA alternative splicing, particularly NF-κB Essential Modulator (NEMO), which is crucial for NF-κB signaling, leading to reduced HCC cell proliferation [93]. Anti-inflammatory and antioxidant effects of melatonin play an important role in the reduction of oxidative stress associated with obesity and fatty liver diseases. These conditions are known to be risk factors for HCC. In addition, melatonin down-regulates pro-inflammatory mediators and thus acts protectively in liver cancer. Melatonin reduces pro-inflammatory mediators like TNF-α and IL-6 involved in the promotion of HCC [95]. Melatonin also causes cell cycle arrest in HCC cells, primarily in the G0/G1 phase. Additionally, melatonin causes the overexpression of the tumor suppressor gene, P53 [96]. Melatonin suppresses the Warburg effect by down-regulating glucose uptake and lactate production, which is essential for the survival of the HCC cells [96]. Studies have shown that serum levels of melatonin are low in liver cirrhosis and HCC patients compared to healthy individuals, though the difference may not reach a significant statistical level [97]. In compensated cirrhosis, circulating melatonin levels have been reported to correlate with disease-related parameters (details relating to blood parameters affected by oxidative stress, inflammation, and liver problems such as malondialdehyde (MDA), C-reactive protein (CRP), TNF-α (tumor necrosis factor-α), ALT (alanine aminotransferase), AST (aspartate aminotransferase), and bilirubin are noted to be associated with levels of circulating melatonin), which suggest a compensation and potentially protective role as the disease progresses [98]. Melatonin may enhance the effectiveness of conventional treatments for HCC, making it a candidate for further clinical trials [98]. Melatonin seems to be an effective adjuvant in chemotherapy and radiotherapy in patients with HCC. Recent studies showed that melatonin sensitizes tumor cells to chemotherapy and radiotherapy by interfering with the DNA repair mechanisms through inhibiting the long non-coding RNA RAD51-AS. Melatonin also reduces the side effects caused by chemotherapy and radiotherapy, thus being beneficial in the management of HCC [99]. It modifies pathways related to drug resistance and hence reduces the resistance to various agents such as sorafenib through pathways like Protein Kinase R-like ER Kinase-Activating transcription factor 4-Beclin1 (PERK-ATF4-Beclin1) [100]. The antioxidant properties of melatonin protect normal tissues against the toxic actions of chemotherapy and radiation by minimizing inflammation and oxidative stress [101]. Data suggest that melatonin may enhance tumor growth inhibition and overall therapeutic response toward standard therapies in HCC patients [94]. It has been reported by one study that high pre-transplantation serum melatonin levels were associated with low one-year mortality rates among HCC patients [102]. By alleviating side effects associated with conventional treatments, melatonin may enhance the quality of life for patients undergoing aggressive cancer therapies [101]. Melatonin signaling in the regulation of hepatic cancer cell growth and survival is multifaceted and interacts with a variety of molecular pathways. It exerts its antitumor effects through modulation of the main signaling pathways involved in cell proliferation, apoptosis, and metabolism. All these interactions open the possibility of melatonin as a therapeutic agent in the treatment of liver cancer [9, 98]. As said, melatonin exerts its actions via specific receptors, mainly MT1 and MT2. Activation of MT1 receptors in HCC cells has been associated with modulation of the levels of cAMP and MAPKs, such as extracellular signal-regulated kinases (ERK), and p38. These signaling pathways are often dysregulated in HCC and are essential to the control of cell growth and survival. This ability of melatonin to regulate the above signaling cascades reinforces its anti-proliferative effects and pro-apoptotic properties [9, 103]. Melatonin suppresses angiogenesis, an event crucial for tumor growth and metastasis, through down-modulation of HIF-1α and signal transducer and activator of transcription 3 (STAT3) signaling. Previous studies using the liver cancer cell line HepG2 under normoxic or hypoxic conditions showed that melatonin reduces VEGF expression by disrupting physical interaction between phosphorylated STAT3, HIF-1α, and transcriptional coactivator/p300/CBP on the VEGF promoter. The tumor cells undergo a reduction in migration and invasion with the anti-angiogenic effect of NF-κB/AP-2β signaling [98, 104]. Melatonin has been shown to modulate the cell cycle of liver cancer cells via alterations in cyclin D1 expression and induction of G0/G1 arrest, which is mediated by upregulation of p53 and its downstream effector p21, resulting in inhibition of cyclin-dependent kinases (CDKs). In HepG2 and Hep3B cells, melatonin raised the Bax/Bcl-2 ratio, activated caspase-3, and induced apoptosis through both intrinsic and extrinsic pathways. Intrinsically, melatonin promoted mitochondrial dysfunction, release of cytochrome c, and activation of caspase-9. Extrinsically, it induced death receptor-mediated pathways related to caspase-8 signaling [96]. Melatonin’s influence on alternative splicing of genes like NEMO, which participates in NF-κB signaling, is an important part of its anti-tumor effects [93]. Melatonin, in combination with other agents like cisplatin, enhances apoptosis and cell cycle arrest, showing potential to improve overall treatment outcomes [105]. It was demonstrated that melatonin inhibits the phosphorylation of ERK1/2, which is required for the epithelial-to-mesenchymal transition in gallbladder cancer cells, and therefore could similarly do so in HCC [106]. By inhibiting ERK signaling, melatonin reduces the invasiveness of the cells and promotes an epithelial phenotype [106]. Melatonin exerts its apoptosis-inducing effect on HCC cells by upregulating p21 and p53, leading to G2/M cell cycle arrest [107]. This apoptotic effect is associated with the downregulation of BMAL, which itself is associated with increased resistance to apoptosis in HCC [108]. Most noticeably, melatonin influences RNA alternative splicing, especially the splicing of gene IKBKG, alias NEMO, involved in NF-κB signaling and thus acting on the pathway MAPK/ERK [93]. Melatonin plays a dual role in autophagy depending on the tumor microenvironment. In H22 tumor-bearing mice, melatonin-induced autophagy was mediated by increased Beclin-1 expression and LC3-II activation along with the suppression of mTOR (mammalian target of rapamycin) and AKT pathways. Blocking autophagy with Beclin-1 RNAi enhanced melatonin-induced apoptosis, suggesting autophagy as a potential therapeutic target. Further, melatonin modulates mitophagy under hypoxia or treatment with chemotherapeutics. In Hep3B cells, melatonin disrupted hypoxia-induced mitophagy by downregulating HIF-1α via the mTORC1/p70S6K pathway, which enhanced the antitumor effects of sorafenib [109]. Melatonin has been shown to potentiate the anticancer efficacy of chemotherapeutic agents such as cisplatin, sorafenib, and doxorubicin by enhancing cancer cell sensitivity and reducing treatment-related toxicity. Melatonin and sorafenib together induce apoptosis through the activation of JNK/c-jun and repress the protective autophagy induced by sorafenib in HCC cells. Similarly, treatment with melatonin, when combined with cisplatin, promotes the apoptotic effect through an intrinsic pathway by regulating Bcl-2 family proteins and inducing active caspases. Besides this, melatonin negatively modulates NF-κB and COX-2 signaling, improving overall the therapeutic response [110, 111]. The PI3K/ AKT/ mTOR pathway is a key regulator of cell growth, survival, and metabolism. Its dysregulation is a common feature in HCC. Melatonin has been identified to inhibit the PI3K/AKT/mTOR pathway through inhibition of the phosphorylation of AKT and mTOR. Inhibition of the pathway leads to inhibited cell growth and increased apoptosis in HCC cells [112]. Melatonin-induced inhibition of the PI3K/AKT/mTOR pathway has caused a reduction in glucose uptake and ATP production and therefore has controlled the Warburg effect. Melatonin has also reduced pro-angiogenic factor expression, such as VEGF, and subsequently inhibits tumor angiogenesis [94, 112]. Melatonin is known to trigger the Hippo signaling pathway, which plays a major role in promoting apoptosis as well as inhibiting cell proliferation of hepatic cancer cells. This pathway is one of the key mechanisms targeted by melatonin in treating HCC because it halts tumor progression when activated [113]. Melatonin may affect the downstream role of the Hippo pathway in modulating the apoptosis and proliferation of HCC cells by regulating RNA splicing of major modulators such as NEMO [93]. Melatonin decreases mitochondrial respiration and glycolysis in HCC cells, indirectly possibly acting on the Hippo pathway due to a change in the cellular energetic state and signaling dynamics [109]. The Hippo-YAP/TAZ pathway maintains a balance between cell growth and apoptosis. Dysregulation, often due to mutations, leads to YAP/TAZ overexpression, promoting excessive cell proliferation and inhibiting apoptosis. Mutations or alterations in the Hippo pathway components, such as MST1/2 and LATS1/2, result in genetic changes [114]. YAP/TAZ translocate into the nucleus upon loss of Hippo signaling to activate oncogenic gene expression [115]. YAP/TAZ promotes cell growth and survival to drive the increase in tumor mass [116]. Coactivators are described in the facilitation of invasive properties of liver cancer cells and also enhancing their metastatic potential [117]. The NF-κB signaling pathway, which is an essential mediator of inflammation, immune response, and cell survival, is frequently dysregulated in HCC, leading to tumor development and chemo-resistance [104]. Melatonin has been reported to inhibit the NF-κB pathway by blocking the nuclear translocation of NF-κB p50 and p65 subunits. This inhibition leads to reduced expression of downstream targets such as cyclooxygenase-2 (COX-2) and interleukin-1β (IL-1β) [104]. Melatonin inhibition of NF-κB equates to decreased inflammation and angiogenesis and enhanced apoptosis in HCC cells. For instance, melatonin therapy is linked with decreased VEGF levels [118]. It has been reported that melatonin enhances the antitumor action of cisplatin by inhibiting NF-κB-mediated survival pathways. The apoptosis induced by cisplatin has been enhanced with this combination therapy in HCC cells by activating caspase-3 and caspase-9, and PARP cleavage [104]. In cell lines of HCC, such as HepG2 and HuH7, melatonin is said to promote the FoxO signaling pathway on a molecular level. Given that FoxO factors are known to govern the cell cycle and apoptosis, control over this pathway by melatonin enhances the anti-cancer properties of melatonin due to apoptosis induction and the inhibition of tumor proliferation [113]. The sphingosine kinase/Sphingosine 1-phosphate (SphK/S1P) pathway is involved in cell survival, migration, and angiogenesis, and its aberrant regulation leads to the development of HCC [119]. It has been reported that melatonin inhibits the SphK/S1P pathway by inhibiting S1P levels and down-regulating the expression of SphK1 and SphK2. Melatonin also upregulates S1P lyase, an enzyme that degrades S1P. Melatonin inhibition of the SphK/S1P pathway has promoted decreased cell proliferation and apoptosis in HCC cells. It further suppressed the expression of cell-cycle-associated proteins, such as Ki67 and cyclin D1, resulting in inhibited tumor growth. Melatonin inhibits the Wnt/β-catenin pathway, involved in carcinogenesis through enhanced cell proliferation and migration. Melatonin also controls microRNA let-7b expression, which suppresses cell growth and invasion and thus has immunomodulatory and proapoptotic effects [118]. Melatonin enhances the sensitivity of HCC to sorafenib, a commonly employed therapeutic drug, through inhibiting autophagy by the PERK-ATF4-Beclin1 pathway. The inhibition reduces the resistance of cancer cells to apoptosis, suggesting synergism when combined with sorafenib [120]. In summary, the receptor-dependent and receptor-independent effects of melatonin in PC are as follows: Receptor-dependent effects of melatonin in HCC: The binding of melatonin to MT1 receptor activates numerous tumor suppressive signaling pathways (NF-kB, PI3K/AKT/mTOR, and MAPK/ERK) that are known to inhibit cellular proliferation and promote cellular apoptosis. Melatonin controls alternative splicing of NEMO, thereby reducing NF-κB activation in HCC cells. Receptor-independent effects of melatonin in HCC: The antioxidant, mitochondrial, and metabolic regulatory properties of melatonin in HCC are, in general, receptor-independent, which include direct scavenging of ROS and NOS, maintenance of mitochondrial membrane potential, enhancement of electron transport chain efficiency, and inhibition of glycolytic reprogramming mediated by the Warburg effect. Downregulation of PD-L1 expression by melatonin, which suppresses HCC cells’ proliferation and migration through regulation of HIF-1α and MAPK/JNK-p38 signaling, are also believed to be receptor-independent. Esophageal cancer (EC) In recent decades, the epidemiology of esophageal cancer (EC) has shown striking global trends and differences. While the overall burden remains substantial, large regional differences in incidence and mortality rates are influenced by socioeconomic factors and lifestyle choices [121]. In 2022, an estimated 511,054 new cases and 445,391 fatalities from EC were reported, with Asia accounting for 75% of cases [122]; while between 1990 and 2019, new cases grew by 67%, whereas age-standardized incidence and mortality rates fell by 19% and 25% [123]. Besides tobacco smoking, high BMI, alcohol drinking, and exposure at the workplace are leading causes of EC deaths among men and women, accordingly [122, 123]. The aging population continues to raise the burden, with incidence shifting to older age groups [121, 123]. The highest incidence and fatality rates are found in East Asia and Southern Sub-Saharan Africa [124]. Esophageal squamous cell carcinoma (ESCC) is reducing, while esophageal adenocarcinoma (EAC) is increasing in high-income nations [125].The aging population continues to raise the burden, with incidence shifting to older age groups [121]. Treatment for EC is complex and mostly based on the kind and stage of the malignancy. The conventional method consists of a mix of radiotherapy, chemotherapy, and surgery, with novel medicines improving therapeutic success [126–128]. For the overall five-year survival rates among patients with locally advanced esophageal cancer, one seldom exceeded 20% in a cure. Such rates were beyond imagination as a relapse rate, as high as 60% of recurrences still occur after treatment with so many therapeutic approaches, surgery, and chemo-radiotherapy included [129]. With a noticeable rise in use over time, combined chemotherapy and radiation therapy have demonstrated better results than radiation alone [130]. In cases where operation is not possible, simultaneous chemo-radiotherapy is the standard of care, while neoadjuvant chemotherapy is common in operable patients [126]. Recent advances have introduced immunotherapy, especially for patients with residual disease post-surgery, to improve disease-free survival rates [131]. The use of checkpoint inhibitors such as trastuzumab, cetuximab, and nivolumab represents potent treatments of EC as their targets are human epidermal growth factor receptor 2 (HER2), EGFR, and VEGFR [132]. Signaling of melatonin in EC Melatonin has emerged as a promising agent in the treatment and prevention of EC cancer, especially ESCS. Its anti-inflammatory, antioxidant, and anticancer properties are multifaceted mechanisms that contribute to its potential efficacy in enhancing conventional therapies and improving patient outcomes [133]. Melatonin, an indirect free radical scavenger, promotes cancer prevention by protecting bone marrow’s myeloid system and regulating immune response. It boosts cellular immunity by boosting interleukin-2 (IL-2), IL-10, and interferon-γ (INF- γ) release [134]. The NF-kB family, activated by stimuli, regulates cell proliferation through two pathways: canonical and non-canonical, influencing gene expression through increased translocation in the nucleus [135]. Combining melatonin with 5-fluorouracil (5-FU) considerably improves chemotherapy efficacy by increasing apoptosis and modulating Enhancer of Zeste Homolog 2 (EZH2) expression [136]. Melatonin suppresses the proliferation and invasion of esophageal cancer cells via blocking the NF-κB signaling pathway and down-regulating matrix metalloprotease-9 (MMP-9) expression [137]. Melatonin has been demonstrated to suppress the HDAC7/β-catenin/c-Myc feedback loop, which is essential for the proliferation of ESCC cells [138]. Melatonin triggers the phosphorylation of p53. Overexpression of P53 is indeed an important factor in chemotherapeutic actions of melatonin and underlines its supporting role in genomic integrity [139, 140]. Melatonin suppresses adenyl cyclase and activates phospholipase C through binding to MT1 and MT2 receptors. This interaction changes the intracellular microenvironment and affects gene expression. Additionally, it links to the cAMP/PKA and MAPK/ERK pathways, mediating activities in a Gi-dependent manner [134]. Melatonin could have a modulating effect on the Enhancer of Zeste Homolog 2/Janus Kinase 2/Signal Transducer and Activator of Transcription 3 (EZH2/JAK2/STAT3) pathway, thereby sensitizing esophageal cancer cells to 5-fluorouracil and other chemotherapeutic agents. This enhancement further increases the apoptosis of cancer cells and reduces cell proliferation, thereby raising the therapeutic efficacy [141]. While melatonin may increase FasL/Fas apoptotic activity in immune cells to boost anti-tumor immune responses, it also inhibits the STAT3 signaling pathway, a key factor in the progression of esophageal carcinoma and immune paradigm shifts [141, 142]. Melatonin also affects tumor growth by deacetylating STAT3 and altering the feedback loops that are involved [143]. Melatonin inhibits the growth of esophageal squamous cell carcinoma by interfering with the HDAC7/β-catenin/c-Myc positive feedback loop, which is essential for Wnt/β-catenin signaling. Melatonin reduces the downstream carcinogenic effects of β-Catenin, a key player in this signaling cascade, by inhibiting its activation [143]. Melatonin appears to consistently slow the progression of esophageal cancer by inhibiting Wnt/β-catenin signaling [144]. Melatonin inhibits the NF-κB signaling pathway in TE-1 esophageal cancer cells, which decreases expression of MMP-9, a key enzyme in mediating cancer invasion and metastasis, leading to the suppressed migration and invasion of esophageal cancer cells [145]. There are not many direct studies on the impact that melatonin has on the PI3K/Akt/mTOR pathway with respect to esophageal cancer. However, this is one important pathway that drives esophageal carcinogenesis and, therefore, may be explored in future therapy of the disease. Since melatonin’s wider anticancer roles suggest that this hormone may have acted through either or both of these pathways to grow and even survive tumors, much supportive general evidence can then be provided on the regulatory impacts of melatonin on related intracellular cascades [146]. Receptor-dependent and receptor-independent effects of melatonin in EC are summarized below: Receptor-dependent effects of melatonin in EC: Melatonin suppresses adenyl cyclase and activates PLC through binding to MT1 and MT2 receptors. This interaction changes the intracellular microenvironment and affects gene expression. Additionally, it links to the cAMP/PKA and MAPK/ERK pathways, mediating activities in a Gi-dependent manner. Receptor-independent effects of melatonin in EC: Melatonin enhances cellular immunity by increasing IL-2, IL-10, and interferon-γ (INF- γ) release. It suppresses the proliferation and invasion of EC cells by blocking the NF-κB signaling pathway and down-regulating MMP-9 expression. It also inhibits STAT3 signaling, increases FasL/Fas-mediated apoptosis, and deacetylates STAT3, affecting feedback regulatory loops involved in tumor growth. It suppresses the HDAC7/β-catenin/c-Myc feedback loop, essential for ESCC proliferation. Melatonin inhibits Wnt/β-catenin signaling and reduces the oncogenic effects of β-catenin. It also induces phosphorylation and overexpression of p53, enhancing its chemotherapeutic actions and supporting genomic integrity. Gastric cancer (GC) Gastric cancer (GC) is recognized as a global concern. In 2020, it resulted in over one million new cases and nearly 769,000 deaths globally, ranking as the fifth most common cancer by incidence and the fourth by mortality [147]. The incidence of this cancer varies by region. Eastern Asia, Eastern Europe, and parts of Central and South America are highly affected by this cancer, whereas most regions in Africa, North America, and Northern Europe have lower relative rates of GC [147, 148]. In 2020, Eastern Asia, with the highest incidence rate, had an age-standardized incidence rate of 32.5 per 100,000 for males and 13.2 per 100,000 for females. In contrast, in North America, these rates were 5.4 and 3.1 per 100,000 for males and females, respectively [147]. GC remains one of the major health problems globally, and its management is fast changing with improvements in surgery, chemotherapy, targeted therapy, and immunotherapy. Although recent developments have made early detection possible, most cases are diagnosed at an advanced stage where treatment is complicated, and the survival rate remains low [149]. Systemic chemotherapy remains a suitable choice for neoadjuvant, perioperative, and postoperative GC. A combination of platinum-based drugs and fluoropyrimidine drugs is a first line. Regimens like FLOT (which includes 5-FU, leucovorin, oxaliplatin, and docetaxel) have shown improved survival in locally advanced disease [150]. In metastatic disease, capecitabine and 5-FU in combination with either cisplatin or oxaliplatin are still first-line treatment options [151]. Combinations with newer agents such as pembrolizumab and nivolumab are showing good benefits [152, 153]. In 2021, the FDA approved nivolumab, an immune checkpoint inhibitor, for the treatment of advanced GC. Recent studies have shown that nivolumab could improve statistically significant survival of patients with advanced gastric cancers [154]. A significant percentage of gastric cancers are identified as HER2-positive. In these cases, trastuzumab is standard care with a HER2-targeted antibody [155]. Also, the addition of pembrolizumab, an immune checkpoint inhibitor targeting the PD-1 pathway, to trastuzumab and chemotherapy could improve the survival rate [156]. Many factors influence the cure rate of GC. The stage of diagnosis is a critical determinant of prognosis. If GC is diagnosed in stage 0, the disease has a survival rate of 90–95%, while in stage IV the survival rate is less than 5% [157]. Early-stage GC is promising. It has a 5-year survival rate between 60% and 80% in IA and IB stages when treated with surgery. However, in stage III of GC, the survival rate decreases between 18% and 50% [158]. Additionally, the treatment strategy can significantly impact the cure rate. Multimodal strategies, including surgery, chemotherapy, and targeted therapies, are crucial for achieving better outcomes [159]. Signaling of melatonin in GC When GC cells are treated with melatonin, the expression level of p-p65 decreases, and this prevents the transcription of some survival genes in these cells [160]. Cyclin D1 and MMP-2 are downstream targets of the NF-κB pathway and play key roles in cancer progression. Cyclin D1 is a protein essential for the G1 to S phase transition of the cell cycle, thereby promoting cell proliferation. This molecule is overexpressed in many cancers, including GC [161]. MMPs are a group of enzymes that play an essential role in tumor invasion. They degrade type IV collagen in the basement membrane of the tumor microenvironment and facilitate tumor metastasis to other tissues [162]. Treatment with melatonin in cancer-associated fibroblasts (CAFs) within the tumor microenvironment has been shown to reduce the expression of MMP2 and MMP9. Additionally, melatonin decreased the levels of cyclin D1 in gastric cancer cells [160]. Bcl-2 is an anti-apoptotic protein that enables cancerous cells to evade apoptosis under stress conditions [163]. It has been shown that the NF-κB pathway can promote the expression of this protein [164]. Therefore, suppression of the NF-κB pathway could inhibit tumor resistance to apoptosis. As mentioned earlier, melatonin suppresses the NF-κB pathway [166]. Moreover, melatonin treatment can change the level of Bcl-2 in a way that facilitates the induction of apoptosis [165]. Overall, the NF-κB pathway appears to play a role in regulating apoptosis as well. In conclusion, the NF-κB pathway acts as a central regulatory hub in gastric cancer progression, and its suppression by melatonin may underlie the inhibition of proliferation, migration, invasion, and the promotion of apoptosis in GC cells. Treating GC cell lines in an in vitro environment with melatonin increases the levels of Bax and Bak, as well as the Bax-to-Bcl-2 ratio. This indicates that melatonin can promote the intrinsic pathway of apoptosis. Tumor necrosis factor receptor superfamily 10 A and 10B (TNFRSF10A and TNFRSF10B) are two types of death receptors that are upregulated in GC cells treated with melatonin. Consequently, melatonin sensitizes these cells to the extrinsic pathway of apoptosis. By this means, melatonin can enhance apoptosis in GC through both intrinsic and extrinsic pathways, elevate caspase enzyme activation, and consequently promote apoptosis [165]. Inositol-requiring enzyme 1 (IRE1) is a transmembrane enzyme that cleaves X-binding protein 1 (Xbp1) mRNA by means of its endoribonuclease activity. This IRE1-Xbp1 axis plays a crucial role in the unfolded protein response (UPR). Additionally, protein kinase RNA (PKR)-like ER kinase (PERK) is another branch of the UPR. When PERK is activated through phosphorylation, it leads to the inhibition of global protein synthesis in the cell [167]. Melatonin can increase IRE1 mRNA, leading to spliced Xbp1 in GC cell lines. Additionally, it enhances PERK phosphorylation in these cells. These findings indicate that melatonin could trigger endoplasmic reticulum (ER) stress in cancerous cells [165]. Prolongation of this condition leads to upregulation of transcription factor c/EBP homologous protein (CHOP), with pro-apoptotic properties [165, 167]. Therefore, the autophagy markers in the cells change in a way that increases autophagy. Microtubule-associated protein 1 A/1B-light chain 3B (LC3B) and Beclin1 increase, while p62 decreases in response to melatonin [165, 168]. Like apoptosis, death receptors play a crucial role in necroptosis and can initiate the necroptosis cascade. Receptor-interacting protein kinase 1 (RIPK1), a death receptor, can be elevated in gastric cancer cells treated with melatonin. Additionally, melatonin upregulates mixed-lineage kinase domain-like pseudo kinase (MLKL), a downstream protein in the necroptosis pathway [165, 169]. The Ras protein is an upstream protein in the MAPK pathway that controls subsequent cascade reactions. Exposing GC cell lines to melatonin causes a significant increase in the H-Ras isoform and a decrease in the N-Ras isoform. This selective regulation possibly shifts the pathway from supporting tumor survival to promoting apoptosis [165, 170, 171]. Following this, c-Raf, a serine/threonine protein kinase, is activated by Ras, which phosphorylates and activates mitogen-activated protein kinase kinase (MEK) 1/2 in the GC cells. Activation of MEK1/2 activates MAPK, which is the downstream molecule in the signaling pathway and controls the final cell response to stress [165, 172, 173]. Treatment with melatonin has been shown to activate the Ras-Raf-MAPK signaling pathway and enhance the cellular stress response, and promote the death of cancer cells under sustained stress conditions [174, 175]. Melatonin treatment has downregulated and upregulated CDK1 and p21 in GC cell lines, respectively [165]. Melatonin has anti-oxidant properties against ROS in H. pylori infection, which may protect against GC [176]. Furthermore, this compound inhibits the proliferation and metastasis of human GC cell lines, MGC-803 and SGC-7901, through the regulation of ROS production [160]. Receptor-dependent and receptor-independent effects of melatonin in GC are summarized below. Receptor‑dependent effects of melatonin in GC: The suppression of the NF-κB pathway (reduced p-p65), accompanied by downregulation of cyclin D1, MMP2, MMP9, and Bcl-2, may involve receptor-mediated signaling, since melatonin receptors are expressed in GI tissue. Receptor-independent effects of melatonin in GC: The induction of intrinsic apoptosis (increased Bax, Bak, and Bax/Bcl-2 ratio), sensitization to extrinsic apoptosis (upregulation of TNFRSF10A and TNFRSF10B), activation of ER stress pathways (IRE1, spliced Xbp1, phosphorylated PERK, and CHOP), modulation of autophagy markers (increased LC3B and Beclin1, decreased p62), and induction of necroptosis (RIPK1 and MLKL upregulation) are closely associated with intracellular stress responses. Similarly, regulation of ROS production, including the protective effects observed during H. pylori infection, reflects the well-established redox-modulating properties of melatonin. Colon cancer (CRC) Colorectal cancer (CRC) is considered the third most common cancer in men and the second most common in women [177]. Overall, it is regarded as the third most common malignancy [178]. Further, it is the third most lethal malignancy in the United States [177, 178]. However, worldwide, CRC is the second leading cause of cancer-related mortality [179]. According to the incidence analysis, the number of new cases is predicted to increase to 3,154,674 new cases in 2040 compared to 1,931,590 new cases in 2020 [178]. In addition, a study in 39 countries reported an increase in the incidence and mortality rate of CRC [180]. This growing number is due to Westernization, this lifestyle, and food habits [178, 179]. Several risk factors have been identified for CRC. The role of environment, genetic variability, dysregulation of intestinal microbiota, and medical history is well recognized [177, 181]. While certain environmental factors, like using dietary fiber, whole grains, dairy products, and dietary supplements like vitamin D3 [177] and calcium [179], are associated with a lower risk of colon cancer and may have beneficial effects [177, 179, 181], others, such as a sedentary lifestyle and obesity [177, 181, 182], smoking, alcohol consumption [177, 181], and the consumption of red and processed meats [177, 182], are related to a risen risk and can contribute to the progression of the disease. In addition, the likelihood of developing CRC rises with increasing age [177]. Among all racial groups, Black people have the greatest incidence of CRC. Plus, in the Black population, CRC presents earlier onset, shorter stage-specific survival time, and a more elevated mortality rate [181, 183, 184]. In addition, one-fourth of the 90% of CRC cases are familial CRC, while the 10% of CRC cases are inherited through single-gene mutations in a Mendelian pattern [177]. So, the role of a family history of CRC in boosting the risk of developing the disease is significant [181]. In addition, significant sex disparities in CRC are seen. Men have approximately 25% higher morbidity and mortality rates than women [185]. Dysregulation of the intestinal microbiota has a major role in the pathophysiology of CRC as well. There is an oral anaerobic bacterium, Fusobacterium nucleatum, which can transit to CRC adenomas through the blood and facilitate the onset and progression of CRC [177, 179]. In other words, dysregulation of gut microbiota and interaction between some special bacteria, like Bacteroides fragilis and Fusobacterium nucleatum, may cause inflammatory responses, which can lead to cancer development in colorectal epithelial cells in the long term [185]. As mentioned previously, the primary source of melatonin in the body is the pineal gland. Interestingly, the GI tract also produces a significant amount of melatonin. Melatonin is widely distributed throughout the gut, with the highest amounts found in the colon and rectum. The GI system contains a community of microbiota that is significantly associated with melatonin. Gut microbiota is one of the factors influencing melatonin production. It can affect melatonin synthesis by activating enzymes responsible for converting serotonin into melatonin. In turn, melatonin modulates the composition of the gut microbiota by promoting the proliferation of beneficial microorganisms and reducing harmful ones. Other effects of melatonin on the gut microbiota include regulation of microbial metabolism, antioxidant and anti-inflammatory activities, and synchronization of microbial activity with the host’s circadian rhythm [186]. The present approach to treating CRC is monotherapy or combinations of chemotherapy, immunotherapy, radiotherapy, and surgical intervention [15]. In contrast, for patients with advanced-stage cancer with metastases, chemotherapy and/or radiotherapy as neoadjuvant therapy may be used before surgery, which is adjuvant therapy [187, 188]. The chemotherapy approaches are based on CRC stages and patient diagnostic data [188]. Current chemotherapy for CRC patients is single-drug regimens or multiple-drug regimens [189]. In the case of single therapy, the first-line treatment includes primarily 5-FU, irinotecan (IRI), capecitabine (CAP or XELODA or XEL), and oxaliplatin (OX). Combined regimens are FOLFOX (5-FU + OX), FOXFIRI (5-FU + IRI), XELOX or CAPOX (CAP + OX), and CAPIRI (CAP + IRI). These combinations are mostly used as first-line treatments [188, 189]. Notably, the rising occurrence of side effects and resistance to chemotherapy has motivated the search for new compounds for the treatment of CRC [190]. Tumor immunotherapy exhibits highly regarded therapeutic promise in CRC. This type of therapy uses monoclonal antibody (mAb) therapy like cetuximab and panitumumab for metastatic CRC. In addition, some studies are underway to use adecatumumab, labetuzumab, and pemtumomab for this cancer. Plus, immune checkpoint inhibitor therapy is a subset of immunotherapy. For example, an ongoing Phase II clinical trial for CRC involves testing Nivolumab and a combination of Nivolumab and Ipilimumab. This trial is working on activating CTLA-4 and PD-1 immune checkpoint signals. Furthermore, cancer vaccines like DC vaccines and OncoVAX are also considered immunotherapy [189]. The success of treatment of CRC has a great variation that can range from 40% to 94% based on treatment type, the stage of the disease, and other prognostic factors. For instance, patients with stage I disease have a cure rate of 94%, while patients with stage IV have a much lower rate of 15% [191]. Also, the role of age is notable as younger patients tend to have better outcomes [192]. Signaling of Melatonin in CRC Melatonin exerts its effects by targeting molecular pathways, cellular structures, and physiological systems, including miR-34a/449a, endoplasmic reticulum, X-linked Inhibitor of Apoptosis Protein (XIAP), lipid metabolism, and gut microbiota [15]. As well, Wnt/β-Catenin, PI3K/AKT/mTOR, and NF-κB pathways have a fundamental role in tumor development and progression that may be modulated by melatonin [112]. Overexpression of the PI3K/AKT/mTOR signaling pathway is demonstrated in CRC. PI3K is a kinase responsible for the phosphorylation of PIP2 (phosphatidylinositol 4,5-bisphosphate) to PIP3 (phosphatidylinositol 3,4,5-triphosphate). PIP3 is a second messenger that plays a role in AKT recruitment. Subsequently, AKT activates mTOR. mTOR can be involved in various parts of tumor growth and development, such as proliferation, metastasis, survival, and angiogenesis. In addition, p38α MAPK is a mediator of resistance to some chemotherapeutic drugs of CRC treatment, such as IRI and 5-FU. Some in vitro and preclinical studies are underway to use MAPK inhibitors in combination therapies [193]. In the context of induction of apoptosis, melatonin activates MAPK and mTOR signaling pathways via ROS [194]. Melatonin also induces apoptosis through dephosphorylation and nuclear import of histone deacetylase 4 (HDAC4). This process causes downregulation of calcium/calmodulin-dependent protein kinase type II alpha chain (CAMKIIα) [99]. CAMKIIα controls the signaling of calcium in cells, which is responsible for the regulation of several cell functions, including apoptosis [195]. In addition, the role of melatonin in promoting apoptosis and inhibiting tumor growth and invasion through the NF-κB pathway is documented [13]. It has been shown that melatonin suppresses the proliferation of CRC cells by reducing DNA synthesis and facilitating cell differentiation through several signaling pathways. For instance, it upregulates the microRNA-34a/449a cluster, which targets anti-apoptotic proteins like Bcl-2 and Notch1 [196]. It is worth noting that miR-532-3p expression is downregulated in CRC. In research, the effect of melatonin on the sensitivity of 5-FU was investigated. As a result, it showed that melatonin promotes the sensitivity of 5-FU by enhancing the expression of miR-532-3p, a microRNA that can regulate the level of β-catenin. β-catenin is a part of the Wnt/β-catenin signaling pathway, which is crucial for preventing uncontrolled cell growth [197]. A study reported that by suppressing HIF-1 transcriptional activity, melatonin reduces tumor angiogenesis of the CRC cell line under hypoxic conditions [13]. Plus, endocan, a pro-angiogenetic factor, is released from cancer cells in hypoxic conditions. Data confirmed that dysregulation of this factor may lead to metastases and poor prognosis of cancer. So, regulation of endocan is one of the ways that can prevent vascularization. As a result, based on the study, melatonin can reduce the level of endocan [198]. In addition, melatonin plays an antiangiogenic role by inactivating Forkhead box protein O (FoxO1) and NF-kB; the expression and release of endothelin-1, a peptide involved in tumor progression, decrease [99]. Melatonin has some protective effects by increasing the integrity of the intestinal mucosal barrier, leading to regulation of the immune response [199]. It has both cellular and humoral immunity, which can lead to increasing the production of antibodies and the amount and activity of cytokines. For example, through nuclear receptors, melatonin stimulates the expression of IL-2 and the secretion of IL-2 and IL-6. Moreover, melatonin is capable of inhibiting the expression of TGF-α and IL-8 in neutrophils mediated by lipopolysaccharide, and it may enhance the number of lymphocytes and the cytotoxic effect of natural killer (NK) cells [185]. Melatonin acts as an antioxidant agent that detoxifies accumulated reactive oxygen or nitrogen species or modulates the balance of pro-oxidant and anti-oxidant enzyme activities by inhibiting pro-oxidative enzymes like xanthine oxidase (XO) and activating antioxidant enzymes such as catalase (CAT), glutathione peroxidase (GPX), and superoxide dismutase (SOD) [15, 199]. However, the effects of melatonin appear to be cell-dependent. In non-malignant cells, melatonin mainly acts as an antioxidant and protects cells from oxidative damage. In malignant cells, it may exert pro-oxidant effects. As an example, based on the in-vitro study, in CRC cells, melatonin increases intracellular ROS levels, leading to oxidative stress-induced apoptosis and promoting autophagy through the endoplasmic reticulum (ER) stress pathway [186]. This selective pro-oxidant effect in cancer cells is considered one of the mechanisms underlying its antitumor activity [200]. Receptor-dependent effects of melatonin in CRC: Inhibition of adenylate cyclase, reduction of cAMP levels, activation of PLCβ, and modulation of mitochondrial signaling through intracellular MT1 receptors are among the receptor-dependent effects of melatonin in CRC. Certain immunomodulatory effects, such as IL-2 stimulation, are mediated via nuclear receptors rather than membrane MT1/MT2 receptors. Receptor-independent effects of melatonin in CRC: Many of melatonin’s reported anticancer effects in CRC, including ROS modulation, regulation of MAPK/mTOR pathways, HDAC4 nuclear translocation, microRNA modulation, inhibition of NF-κB and HIF-1 activity, and antioxidant enzyme activation, do not directly affect MT1/MT2 receptors and appear to be receptor-independent. Gallbladder cancer (GBC) Gallbladder cancer (GBC) is the most common cancer of the biliary tract, but the sixth most common cancer of the GI tract. This tumor has an extremely high mortality rate. The importance of an early diagnosis cannot be overemphasized because later discoveries of GBC grow so insidiously [201]. Many risk factors influence the epidemiology of GBC, especially in high-incidence areas like India. The most important among these include gallstones, environmental exposures, and chronic infections, which have been thought to act synergistically in increasing susceptibility to this malignancy [202]. Cholelithiasis [203], exposure to pollutants, heavy metals, and contaminated water, sedentary lifestyle, and high-fat diets have been linked to increased GBC risk [203]. Chronic inflammation in conditions like chronic Salmonella typhi and Helicobacter pylori infections creates a chronic inflammatory state that promotes carcinogenesis [204]. The GBC has a notably low cure rate because this cancer is often diagnosed in late stages and has a poor prognosis [205]. A retrospective cohort study analyzed 331 GBC patients who had surgical resections between 2000 and 2013 and followed them over 10 years. These patients exhibit a 10.88%. Cure rate. The reasons for this bad prognosis were positive lymph node metastasis, T3–4 stages, hepatic invasion, and R1 resection [206]. Another study reported a mean survival of 36.6 months and a 43.6% survival rate at 10 years among 52 patients who underwent curative resection [207]. If the disease is diagnosed in the early stages, it generally has a high cure rate because treatment can effectively remove or control the tumor with surgery and/or other interventions. In early-stage GBC, the likelihood of complete remission is significantly higher. In contrast, in advanced stages, cancer can spread to other organs or lymph nodes. This can make the treatment more challenging. In these cases, advanced stages mainly require palliative care to manage symptoms and improve quality of life. Additionally, the efficacy of chemotherapy and radiotherapy in advanced GBC remains limited. Therefore, treatment in late-stage disease focuses more on symptom management rather than cure [208]. Routine treatment options for GBC include gemcitabine and cisplatin. About one-third of patients can undergo surgery after chemotherapy [209–211]. Also, Durvalumab, a novel development in immunotherapy, shows potential when paired with chemotherapy [212]. Signaling of melatonin in GBC Melatonin has an important role in gallbladder health by regulating bile secretion and antioxidative effects. The ROS, which can be produced for many reasons, could lead to several pathophysiological problems, such as malignancy [213]. Elevating ROS in the cell can damage cell components like DNA, lipids, and proteins, potentially inducing apoptosis [214]. In vitro exposure of the GBC cells to melatonin elevated ROS production, and therefore apoptosis was induced in the cell [215]. It was also reported that melatonin induced apoptosis at high concentrations [106]. Additionally, melatonin could exert anticancer effects by suppressing the PI3K/Akt/mTOR signaling pathway. This causes inhibition in cell proliferation and enhancement in apoptosis [215]. The GBC, like many other cancers, is characterized by its invasion and migration ability. This invasion is the result of molecular signaling pathways such as epithelial-mesenchymal transition (EMT), which can promote tumor aggressiveness and enable it to spread in distant tissues [216]. It has been proven that melatonin can inhibit EMT-activating factors in many cancers [217]. In GBC, melatonin shows its inhibitory effect on invasion via suppressing the EMT pathway [106]. Additionally, melatonin reduced the motility of GBC cell lines in an in vitro environment [215]. Melatonin effectively stops the ERK pathway, often overactivated in GBC cells. This overactivity in GBC cells is hereby inhibited, which leads to reduced invasiveness and EMT, which is important for metastasis in cancer cells. In conclusion, melatonin shows its anti-cancer effect in GBC through several mechanisms. Induction of apoptosis, suppression of cell proliferation, and inhibition of cell invasion through EMT are the main mechanisms [106]. Melatonin affects the activity of the PI3K/Akt/mTOR signaling pathway, which is one of the most affected pathways concerning cell survival and proliferation. Inhibition of the PI3K/Akt/mTOR pathway results in autophagy in gallbladder cancer cells; thus, by inducing ROS, melatonin further inhibits proliferation and invasion [215]. Receptor‑dependent and receptor-independent effects of melatonin in GBC are as follows: Receptor‑dependent effects of melatonin in GBC: Melatonin could exert anticancer effects by suppressing the PI3K/Akt/mTOR signaling pathway. This causes inhibition in cell proliferation and enhancement in apoptosis. Melatonin effectively stops the ERK pathway, which is often overactivated in GBC cells. This overactivity in GBC cells is hereby inhibited, leading to reduced invasiveness and EMT, which is important for metastasis in cancer cells. Melatonin shows its anti-cancer effect in GBC through several mechanisms. Induction of apoptosis, suppression of cell proliferation, and inhibition of cell invasion through EMT are the main mechanisms. Receptor‑independent effects of melatonin in GBC. Melatonin elevates ROS production and induces apoptosis in GBC. Figure1 illustrates the effects of melatonin on signaling pathways involved in various gastrointestinal cancers. Fig. 1The effects of melatonin on signaling pathways involved in various gastrointestinal cancers. Melatonin exerts its anticancer effects by inhibiting the signaling pathways of P-AKT/AKT, PDGFR-β/STAT3, mTOR, SphK/S1P, Wnt/β-Catenin, ERK, HIF-1 & FoxO1, PI3K/AKT/mTOR, NF-κB, and MGLL. Melatonin also applies its anticancer effects by inducing several other signaling pathways, such as MAPK, TLR4/NF-κB/NLRP3, Hippo, JNK/c-jun, PERK-ATF4-Beclin1, EZH2/JAK2/STAT3, Ras/Raf/MEK, PERK, ER stress, Bax and Bak, thus suppressing inflammation, proliferation, tumor growth, migration, invasion, autophagy, and angiogenesis. AKT: Protein kinase B, PDGFR-β: Platelet-derived growth factor receptor beta, STAT3: Signal transducer and activator of transcription 3, mTOR: mammalian target of rapamycin, SphK/S1P: Sphingosine kinase/ sphingosine-1-phosphate, ERK: extracellular-signal-regulated kinase, HIF-1: Hypoxia-Inducible Factor-1, FoxO: Forkhead box protein O, PI3K: phosphatidylinositol 3' –kinase, NF-κB: Nuclear factor-κB, MGLL: monoacylglycerol lipase, MAPK: mitogen-activated protein kinase, TLR4: Toll-like receptor 4, NLRP3: NOD-, LRR- and pyrin domain-containing protein 3, JNK/c-jun: c-Jun N-terminal kinases, PERK: Protein Kinase R-like ER Kinase, ATF4: Activating transcription factor 4, EZH2: Enhancer of zeste homolog 2, JAK2: Janus kinase 2, Ras/Raf/MEK: mitogen-activated protein kinase, PERK: protein kinase R-like endoplasmic reticulum kinase, ER: Endoplasmic reticulum, Bax: Bcl-2-associated X protein, Bak: Bcl-2 antagonist killer 1 The effects of melatonin on signaling pathways involved in various gastrointestinal cancers. Melatonin exerts its anticancer effects by inhibiting the signaling pathways of P-AKT/AKT, PDGFR-β/STAT3, mTOR, SphK/S1P, Wnt/β-Catenin, ERK, HIF-1 & FoxO1, PI3K/AKT/mTOR, NF-κB, and MGLL. Melatonin also applies its anticancer effects by inducing several other signaling pathways, such as MAPK, TLR4/NF-κB/NLRP3, Hippo, JNK/c-jun, PERK-ATF4-Beclin1, EZH2/JAK2/STAT3, Ras/Raf/MEK, PERK, ER stress, Bax and Bak, thus suppressing inflammation, proliferation, tumor growth, migration, invasion, autophagy, and angiogenesis. AKT: Protein kinase B, PDGFR-β: Platelet-derived growth factor receptor beta, STAT3: Signal transducer and activator of transcription 3, mTOR: mammalian target of rapamycin, SphK/S1P: Sphingosine kinase/ sphingosine-1-phosphate, ERK: extracellular-signal-regulated kinase, HIF-1: Hypoxia-Inducible Factor-1, FoxO: Forkhead box protein O, PI3K: phosphatidylinositol 3' –kinase, NF-κB: Nuclear factor-κB, MGLL: monoacylglycerol lipase, MAPK: mitogen-activated protein kinase, TLR4: Toll-like receptor 4, NLRP3: NOD-, LRR- and pyrin domain-containing protein 3, JNK/c-jun: c-Jun N-terminal kinases, PERK: Protein Kinase R-like ER Kinase, ATF4: Activating transcription factor 4, EZH2: Enhancer of zeste homolog 2, JAK2: Janus kinase 2, Ras/Raf/MEK: mitogen-activated protein kinase, PERK: protein kinase R-like endoplasmic reticulum kinase, ER: Endoplasmic reticulum, Bax: Bcl-2-associated X protein, Bak: Bcl-2 antagonist killer 1 Clinical evidence and translational challenges of melatonin in GI cancers While most of the evidence for the anticancer effects of melatonin for GI cancers is from in vitro and in vivo studies, a number of clinical studies have explored its efficacy as an adjunct agent. Early clinical studies of advanced solid tumors, including hepatocellular carcinoma and colorectal cancer, have shown that when melatonin (usually 20 mg/day orally) is added to standard chemotherapy, patients experience better overall survival and lower toxicity from chemotherapy [30]. Melatonin dosing and safety Within various clinical trials, melatonin has been effective in chemotherapy-induced toxicity reduction at doses between 10 and 20 mg/day [218]. Further studies using melatonin in addition to chemotherapies are warranted because there are virtually no chronic or acute toxicities associated with melatonin use, even in high doses. to provide its “chemo-protective” effects, it is likely that doses much higher than the recommended physiological doses of melatonin (for example, 1 mg/kg) would be necessary [219]. Enhancement of chemotherapy efficacy In addition to its toxicity-lowering effects, melatonin has been shown to possibly augment the effectiveness of chemotherapy and decrease chemoresistance. Melatonin decreases the activity of the ATP-Binding Cassette (ABC) transporter, the most commonly known drug efflux and chemoresistance mechanism. Furthermore, melatonin can reverse cisplatin chemoresistance through inhibition of the Wnt/β-catenin pathway [219]. Effective concentrations in in vitro and in vivo studies In vitro studies Pharmacological Concentration: Melatonin’s pharmacological dose producing anticancer effects in vitro is a concentration of 1 mM. One mM melatonin can have anti-metastatic effects on breast cancer cell lines by decreasing cell viability and cell invasiveness. It can also decrease the expression of VEGF, which would inhibit angiogenesis in breast cancer cells. One mM melatonin also greatly decreases the proliferation of pancreatic carcinoma cells and also greatly decreases VEGF [220]. Physiological Concentration: One nM melatonin is a physiological concentration and has also been shown to exert some antiproliferative effects and trigger apoptosis in breast, prostate, and ovarian cancer cells [220]. In vitro cell culture studies have also shown that melatonin at physiological concentrations can inhibit cell proliferation and invasion [221]. In vivo studies Pharmacological Doses: Numerous in vivo studies have looked at various pharmacological doses of melatonin in order to demonstrate anticancer effects. For instance, doses like 10 mg/kg for rats, 100 mg/kg for rats, and 250 mg/kg for mice have been administered [222]. One particular study showed that tumor-bearing mice treated with 10 mg/kg of melatonin and 5 mg/kg of cisplatin, melatonin reduced DNA damage, and also enhanced the anticancer effects of cisplatin [220]. Normal Dose Levels: In clinical practice, normal dose levels of 10 to 50 mg per day have been documented in cases of breast cancer, metastatic renal melanoma, and non-small cell lung cancer, with other types of cancers also in vivo [223]. Translation to achievable human plasma levels in cancer In the elderly, the physiological concentrations of melatonin in blood serum are 0.10–0.51 nM when measured at night. Melatonin’s average maximal serum concentration is significantly elevated to 1.75 and 17.24 nM, respectively, when administered in pharmacological doses of 0.4 and 4 mg. However, it is swiftly eliminated, with a half-life of 45 min [224]. Conclusion Repurposing drugs has gained substantial attention in recent years. One of the major advantages of drug repositioning is that enormous data regarding the drug’s pharmacokinetic properties and toxicities are often available, which reduces the need for extra studies. Although in a new setting, repurposing of a drug with new indications will necessitate validation and new clinical trials. Bypassing major fundamental studies regarding the pharmacokinetics and toxicity of a drug lessens the annual cost of introducing a new drug to the market. With limited budgets available, it is important to prioritize the funding of research that has the greatest potential to efficiently improve health outcomes. Melatonin is a drug with multiple dosage forms, limited side effects, and reasonable efficacy. It is secreted by the brain and exerts its biological actions on various tissues by coupling to its two receptors, MT1 and MT2. Activation of these receptors leads to affecting multiple critical signaling pathways, which are dysregulated in many illnesses such as different malignancies. Reducing the side effects of chemotherapy and radiotherapy has also been documented with the use of melatonin. To date, nearly 50 clinical trials have been conducted on the anticancer effect of melatonin in cancer therapy, all demonstrating significant and promising results. Along with the many beneficial effects of melatonin in cancer, there is also a shortage of data that should be investigated in the future. Investigation on large-scale human trials with diverse ethnicities, achieving the desired doses of melatonin with anticancer properties in clinical settings, and investigation on the possible drug-drug interactions between melatonin and conventional chemotherapeutic regimens are among the limitations of the studies. This review focused on the epidemiology of GI cancers and the effect of melatonin in each dysregulated signaling pathway. Considering the global rising incidence of GI cancers, the addition of a drug with a safe profile and anticancer properties like melatonin may both upscale the anticancer effects of chemotherapeutic agents and enhance patients’ quality of life. Therefore, melatonin can be anticipated as a novel therapeutic adjuvant to conventional chemotherapeutic regimens with the intention of augmenting patients’ outcome as well as her/his quality of life.